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1  | INTRODUC TION
SMG1 and ATM are members of the PI3‐kinase–like kinase (PIKK) 
family of proteins. Other members of this family include ATR, 
DNA‐PKcs and mTOR. ATM is a well‐known tumour suppressor 
playing important roles in DNA damage repair and in responses 
to oxidative stress. In humans, loss of ATM causes the disease 
ataxia telangiectasia (A‐T) which is characterized by progressive 
neurodegeneration, immunodeficiency and cancer development; 
however, the progression of disease can be markedly different be‐
tween individual cases.1 Atm	knockout	(−/−)	mice	are	prone	to	the	
development of thymic lymphomas, are radiosensitive and show ev‐
idence of oxidative damage to tissues.2‐4 Furthermore, loss of ATM 
and the resultant accumulation of unrepaired DNA damage can 
lead to activation of innate immune pathways and basal inflamma‐
tion.5,6 SMG1 has a well‐characterized role in nonsense‐mediated 
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Abstract
Suppressor of morphogenesis in genitalia 1 (SMG1) and ataxia telangiectasia mutated 
(ATM) are members of the PI3‐kinase like–kinase (PIKK) family of proteins. ATM is a 
well‐established tumour suppressor. Loss of one or both alleles of ATM results in an 
increased risk of cancer development, particularly haematopoietic cancer and breast 
cancer in both humans and mouse models. In mice, total loss of SMG1 is embryonic 
lethal and loss of a single allele results in an increased rate of cancer development, 
particularly haematopoietic cancers and lung cancer. In this study, we generated mice 
deficient in Atm and lacking one allele of Smg1, Atm−/−Smg1gt/+ mice. These mice de‐
veloped cancers more rapidly than either of the parental genotypes, and all cancers 
were haematopoietic in origin. The combined loss of Smg1 and Atm resulted in a 
higher level of basal DNA damage and oxidative stress in tissues than loss of either 
gene alone. Furthermore, Atm−/−Smg1gt/+ mice displayed increased cytokine levels in 
haematopoietic tissues compared with wild‐type animals indicating the development 
of low‐level inflammation and a pro‐tumour microenvironment. Overall, our data 
demonstrated that combined loss of Atm expression and decreased Smg1 expression 
increases haematopoietic cancer development.
K E Y W O R D S
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decay (NMD), the pathway used by cells to detect and degrade 
mRNA with premature termination codons which may code for 
truncated proteins.7 SMG1 has previously been implicated in regu‐
lation of DNA damage responses, telomere maintenance and oxida‐
tive and hypoxic stress responses and stress granule formation.7‐11 
Complete loss of SMG1 expression in mice is lethal early during 
embryogenesis but we have demonstrated that loss of a single 
SMG1 allele increased cancer development, particularly lung ade‐
nocarcinomas and lymphomas.12 SMG1 haploinsufficiency in these 
mice did not result in sufficient protein loss to affect its roles in 
nonsense‐mediated decay, DNA damage responses or apoptosis in‐
duction. However, SMG1‐deficient animals showed elevated levels 
of basal inflammation and oxidative damage to tissues prior to de‐
velopment of cancers indicating a potential role for these pathways 
in enhancing tumourigenesis in this model. SMG1 and ATM have 
previously been shown to co‐regulate DNA damage responses 
and p53 signalling.13,14 Brumbaugh et al (2004) demonstrated that 
both enzymes contribute to the phosphorylation of Upf1 and p53 
in response to ionizing radiation (IR). Further SMG1 and ATM are 
both required for maximal activation of the G1/S checkpoint fol‐
lowing exposure to ionising radiation or during oxidative stress.13,14 
SMG1 can also regulate alternative splicing of p53 in response to 
DNA damage.15 To further examine the interplay between SMG1 
and ATM in cancer development, we crossed mice heterozygous 
for both the Smg1 genetrap allele (Smg1gt/+) and the Atm null allele 
to generate Atm knockout mice that were also heterozygous for 
Smg1 (Atm−/−Smg1gt/+). These mice were viable and developed lym‐
phomas at a more rapid rate than mice carrying only the Atm−/− or 
Smg1gt/+ alleles.
2  | MATERIAL S AND METHODS
2.1 | Generation of Atm−/−Smg1gt/+ mice and animal 
husbandry
Parental strain Atm−/− and Smg1gt/+ mice have been described 
previously.12,16 Animals heterozygous for both alleles were bred 
to generate Atm−/−Smg1gt/+ mice, and sex of parents carrying 
each genotype was alternated during breeding. All animal ex‐
periments were approved by the animal ethics committees of 
Western Sydney University, The University of Queensland or 
QIMR Berghofer Medical Research Institute and were conducted 
in accordance with the ‘Australian Code for the Care and Use of 
Animals for Scientific Purposes (2013)’. Mice were housed in ei‐
ther the QIMR Berghofer Medical Research Institute or Ingham 
Institute for Applied Medical Research animal facilities. Mice were 
kept on a 12:12 hour light: dark room cycle. Food and water were 
available ad libitum throughout the course of all experiments. 
F I G U R E  1   Combined Atm loss and Smg1 heterozygosity decreases mouse lifespan. A, Smg1+/gt mice were bred with Atm+/− mice to 
generate Smg1+/gt Atm−/− animals. Kaplan‐Meier survival curve shows that combined loss of Atm and Smg1 significantly decreases lifespan. 
B, Smg1+/gt mice were also crossed to generate Smg1+/gtp53−/− animals. SMG1 heterozygosity had no additional effect on lifespan in these 
animals as demonstrated by Kaplan‐Meier survival curve. C, Median lifespan for each of the mouse lines examined as determined using 
Kaplan‐Meier analysis in GraphPad Prism. ***P < .001, ****P < .0001
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Genomic DNA was extracted from ear clips for genotyping as de‐
scribed previously.12
2.2 | Isolation and culture of mouse embryonic 
fibroblasts (MEFs)
Mating of mice was assumed at midnight and timed from 0.5. 
E14.5 embryos were isolated and brain and liver removed, and 
then trypsinized as described previously.12 MEFs were then 
plated on 0.1% gelatine‐coated T25 flasks and incubated at 37°C 
with 5% CO2 in DMEM (Thermo Fisher) supplemented with 12% 
heat‐inactivated foetal calf serum (Thermo Fisher), 1% penicillin/
streptomycin (Thermo Fisher), 1% glutamax (Thermo Fisher), 1x 
non‐essential amino acid (Thermo Fisher) and beta‐mercaptoe‐
thanol (Sigma). Experiments on primary MEFs were performed at 
passages 4‐5.
2.3 | Histology
Tissues were isolated and fixed in 10% formalin. Samples were pro‐
cessed by the QIMR Berghofer histology facility. Serial sections 
of 4μm thickness were used for haematoxylin and eosin staining 
or immunofluorescence for 8‐oxo‐dG or 4HNE as described pre‐
viously.17 Images were scanned using Aperio Turbo or Aperio FL 
(Leica Biosystems) and analysed using ImageScope software (Leica 
Biosystems). Histology slides were examined by an experienced 
pathologist.
2.4 | Irradiation and DNA damage analysis
Cells were irradiated at 6Gy with a GammaCell40Exactor (Best 
Theratronics Ltd.) with a Cobalt60 source of 960c Gγ/min. Cells 
were fixed with 4% paraformaldehyde in phosphate‐buffered saline 
(PBS) at indicated time‐points. γH2AX analysis by immunofluores‐
cence was performed as described previously.18
2.5 | Flow Cytometry—cell death assays, cytokine 
bead assays and cell surface markers
Flow cytometry was performed with a FACSCanto or Fortessa (BD 
Biosciences). Annexin V (BD Pharmingen) apoptotic analysis was 
performed according to manufacturer's instruction. Propidium io‐
dide (Sigma) cell cycle analysis was performed as described previ‐
ously.19 Measurement of serum cytokines levels was performed with 
cytokine bead array,20 and staining for cell surface markers was per‐
formed as described previously.21,22
2.6 | Quantitative PCR
Real‐time PCR reactions were performed as described previously 
23 and analysed using an Applied Biosystems QuantStudio (Thermo 
Fisher). Primer sequences are shown in the table below.
Target gene
Forward primer 
5′‐3′
Reverse primer 
5′‐3′ Ref
Interleukin‐1β CAACCAACAA 
GTGATATTCTC 
CATG
GATCCACACTC 
TCCAGCTGCA
23
CSF‐1 CCACCATCCAC 
TTGTATGTCAA 
AGAT
CTCAACCACTG 
TCACCTCCTGT
24
Rpl13a GAGGTCGGGTG 
GAAGTACCA
TGCATCTTGGC 
CTTTTCCTT
25
Interleukin‐6 GATTGTATGAA 
CAACGATGATGC
TGTTCTTCATGT 
ACTCCAGGTAGC
12
IFNβ CCACAGCCCTCT 
CCATCAAC
TGAAGTCCGCCC 
TGTAGGTG
23
2.7 | Statistical analysis
Graphing and statistical evaluation was performed with GraphPad 
Prism 6 (GraphPad Software, USA). The Kaplan‐Meier function 
was used for survival curves and to estimate the median survival. 
Differences between survival curves were calculated using a log‐
rank test. t Test with Welch's correction for unequal variance was 
used for all other comparisons. Differences were considered to be 
significant if P	≤	.05.	Data	are	presented	as	mean	±	standard	error	of	
the mean from at least three independent experiments unless oth‐
erwise indicated.
3  | RESULTS
3.1 | Generation of Atm−/−Smg1gt/+ mice
The Smg1 Genetrap line (Smg1gt/+) and Atm knockout mice (Atm−/−) 
have been described previously.12,16 Animals heterozygous for both 
alleles were bred to generate Atm−/−Smg1gt/+ mice. Animals were 
generated at approximately the expected frequency (1/7, when ac‐
counting for lethality of Smg1 knockout animals).
3.2 | More rapid lymphoma development in 
Atm−/−Smg1gt/+ mice
Atm−/−Smg1gt/+ mice were aged alongside littermate controls to ex‐
amine spontaneous cancer development. Atm−/−Smg1gt/+ mice had 
a significantly shorter lifespan than either Atm−/− or Smg1gt/+ mice 
(Figure 1A&C). Atm−/−Smg1gt/+ mice had a median lifespan of 203 days 
compared with 373 days for Atm−/− and 630 days for Smg1gt/+ ani‐
mals. At autopsy, Atm−/−Smg1gt/+ animals were observed to have 
enlarged thymus and spleens. Tissue samples were taken and fixed 
in 10% formalin, then paraffin‐embedded, H&E‐stained and exam‐
ined by a pathologist. All Atm−/−Smg1gt/+ mice showed evidence of 
blood cancer development in either the spleen or thymus with small 
numbers of animals showing evidence of other pathologies such as 
steatosis, chronic inflammation or extramedullary haematopoiesis 
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(Table 1). Further immunohistochemistry was performed on a subset 
of haematopoietic tumours to support pathology findings. Examples 
of results for IHC for B220 (B cell marker), MPO (myeloid marker), 
CD3 (T cell marker) and Bcl2 are in Figure S1. This cancer profile is 
more similar to the Atm−/− animals which also developed lympho‐
mas in the majority of animals (80%, Table 1), in contrast Smg1gt/+ 
mice who developed a combination of lymphomas and papillary lung 
adenocarcinomas as we have described previously (Table 1).12 We 
performed a similar experiment crossing Smg1gt/+ mice to p53−/− 
mice. In contrast to the results with Atm−/− crosses, SMG1 haplo‐
insufficiency had no effect on the rate of tumour development in 
p53−/− mice (Figure 1B‐C) nor on the types of tumours developed in 
p53−/−Smg1gt/+ animals (Table 1). IHC was also performed with exam‐
ples in Figure S2. These data indicate that decreased SMG1 expres‐
sion exacerbates the pro‐oncogenic effect of ATM loss, potentially 
by increasing the dysregulation of a pathway in which both SMG1 
and ATM provide regulatory feedback or by a combined effect on 
independently regulated pathways.
3.3 | Effect of combined loss of SMG1 and ATM on 
haematopoietic cell composition
Given the predominance of lymphoma formation in Atm−/−Smg1gt/+ 
mice, we examined whether the addition of Smg1 heterozygosity 
resulted in increased defects in the immune system compared with 
the known decrease in T cells caused by loss of ATM expression.2,3 
We showed previously that SMG1 heterozygosity alone did not sig‐
nificantly alter the composition of immune system prior to disease 
onset.12 Here we analysed the composition of circulating blood cells 
and lymphocytes in the spleen, thymus and lymph nodes. There 
were no significant differences in the major circulating cell popula‐
tions between any of the genotypes (Figure 2A). As expected Atm−/− 
animals showed a decreased number of both CD4+ and CD8+ T 
cells in spleen and lymph nodes (Figure 2B), this decrease was not 
affected by SMG1 heterozygosity. The percentage of CD19 posi‐
tive B cells was increased in all animals lacking ATM expression in 
both the spleen and lymph node, and this is seen as the balance to 
TA B L E  1   Pathology results from tissues analysed from the different genotypes of mice
Tissue
Wild‐type 
(n = 10) Smg1+/gt (n = 12) Atm−/− (n = 8)
Smg1+/gt Atm± 
(n = 8) Smg1+/gt Atm−/− (n = 16)
Smg1+/gt 
p53−/− (n = 6)
Thymus  DLCL (4) DLCL (2), 
lympho‐
blastic lym‐
phoma (2)
FCL (1), lymphoma 
(1), large cell 
lymphoma (1)
Lymphoblastic lymphoma 
(2), DLCL (4), small cell 
lymphoma (1)
Lymphoma 
Burkitt‐like (4)
Liver Large cell 
lymphoma (1), 
chronic inflam‐
mation (2)
Steatosis (3), DLCL 
(1), lymphoma (1), 
chronic inflam‐
mation (1)
Steatosis (3), 
lympho‐
blastic 
lymphoma 
(1), hepatitis 
(1)
Cavernous 
haemangioma 
(2), steatosis 
(2), spindle cell 
haemangioen‐
dothelioma (2), 
FCL (1), chronic 
inflammation (1)
Myeloid leukaemia 
(1), lymphoblastic 
lymphoma (1), DLCL (4), 
steatosis (1)
 
Spleen Large cell 
lymphoma (1), 
EMH (4), hy‐
perplasia (1)
EMH (4), hyperpla‐
sia (1), DLCL (4), 
lymphoma (1)
DLCL (1), 
EMH (2), 
hyperplasia 
(1), lympho‐
blastic lym‐
phoma (1),
FCL (1), DLCL (1), 
EMH (1), hyper‐
plasia (1), hairy 
cell leukaemia (1)
Myeloid leukaemia 
(2), lymphoblastic 
lymphoma (2), DLCL(6), 
EMH (1), hyperplasia 
(1), marginal zone lym‐
phoma (1)
EMH (1), FCL (1), 
hyperplasia (1)
Kidney Chronic inflam‐
mation (1)
Chronic inflamma‐
tion (3), DLCL(2), 
lymphoma (1)
  Lymphoma (1), atypical 
lymphoid infiltrate(1), 
chronic inflammation (1)
 
Lung Chronic inflam‐
mation (1), 
lymphoid 
infiltrate (1)
Papillary adeno‐
carcinoma (5), 
DLCL (1), chronic 
inflammation (2),
DLCL (2), 
papillary 
adenocarci‐
noma (1)
Chronic inflamma‐
tion (1), papillary 
adenocarcinoma 
(5), FCL (1), DLCL 
(1)
Myeloid leukaemia 
(1), lymphoblastic 
lymphoma (1), DLCL(3), 
focal lymphoma (1)
Lymphoma 
Burkitt‐like (2)
Large 
Intestine
    Myeloid leukaemia (1)  
Bone   Lymphoma (1)    
Heart  DLCL (1)   Lymphoma (1)  
Other Large cell lym‐
phoma (1)
 Sarcoma (1) Epidermal cyst (1)  High‐grade sar‐
coma (2)
Ovary    Serous cysts (1)   
Abbreviations: DLCL, Diffuse large cell lymphoma; EMH, extramedullary haematopoiesis; FCL, follicular cell lymphoma.
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F I G U R E  2   Smg1 heterozygosity in addition to Atm loss does not alter lymphocyte profile compared with Atm−/− mice. Pre‐disease animals 
(3‐5 mo) were killed and spleen (A), lymph nodes (B) and thymus (C) harvested. Single‐cell suspensions were generated, cell surface marker 
staining was performed for major lymphocyte populations, and samples were analysed by flow cytometry. Bars show the mean and error 
bars the standard error of the mean. Statistical significance was assessed using a t test with Welch's correction for unequal variance. *P < .05
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the decreased percentage of T cells and is expected. In Atm−/− mice, 
there is an increased number of double‐positive T cells. ATM is im‐
portant for repair of the DNA damage induced during VDJ recombi‐
nation, and as such, there is a partial block in T cell differentiation in 
these animals. This increase was not observed in Atm−/−Smg1gt/+ mice 
although there was an increase in double‐negative T cells which was 
not statistically significant (Figure 2C). As this difference does not 
translate to a difference in tissue T cell populations between Atm−/− 
and Atm−/−Smg1gt/+ mice, it is unlikely to be contributing to tumour 
development differences between these animals.
3.4 | Effect of Smg1 haploinsufficiency on DNA 
damage responses and oxidative stress
In both Atm−/− and Smg1gt/+ mice, high levels of oxidative dam‐
age to tissues have been detected.12,16 We examined tissues from 
Atm−/−Smg1gt/+ mice and the parental genotypes to determine 
whether like DNA damage, oxidative damage was increased. Splenic 
tissue from pre‐disease mice was stained for the presence of 8‐oxo‐
dG, a product of oxidative damage to DNA. Whereas there was lim‐
ited detectable 8‐oxo‐dG signal in wild‐type animals, there was a 
low level of damage in Smg1gt/+ mice as we have reported previously, 
this further increased in Atm−/− animals and again there was more 
damage detected in Atm−/−Smg1gt/+ mice (Figure 3A). We further 
examined damage by staining splenic section for 4‐hydroxynonenal 
(4HNE) a product caused by lipid peroxidation in response to in‐
creased reactive oxygen or nitrogen species. 4HNE staining was also 
increased in Atm−/−Smg1gt/+ mice to a greater degree than in either 
Smg1gt/+ or Atm−/− animals (Figure S3). ATM has a well‐established 
role in the DNA damage response.26 We previously showed that 
the level of SMG1 protein expressed in Smg1gt/+mice was sufficient 
for its roles in DNA damage repair.12 However, others have shown 
that combined loss of ATM and SMG1 in cell lines leads to increased 
basal DNA damage and alterations to DNA repair pathways.8,14 To 
determine whether the combined roles of SMG1 and ATM in DNA 
repair was recapitulated in vivo, we examined the formation and 
resolution of γH2AX foci in Atm−/− compared with Atm−/−Smg1gt/+ 
murine embryonic fibroblasts (MEFs). γH2AX is recruited to sites of 
DNA double‐strand breaks and remains present at the break until 
it is repaired; thus, by measuring the changes in the number of foci 
we could determine whether the kinetics of DNA repair was altered 
by SMG1 haploinsufficiency on an Atm−/− background. MEFs were 
exposed to a moderate dose of 5Gy irradiation (IR), and the number 
of foci present in the nucleus of at least 50 cells was determined at 
baseline and 1, 2 and 24 hours post‐IR (Figure 3B). At baseline, it 
was clear that there was a larger number of γH2AX foci in cells from 
Atm−/− mice and that this was further increased in Atm−/−Smg1gt/+ 
mice (Figure 3C example images). Following irradiation, a similar 
level of damage was observed in all genotypes but the rate of re‐
pair was slower in Atm−/− and Atm−/−Smg1gt/+ compared with Smg1gt/+ 
and wild‐type mice with a greater number of foci remaining at 2 and 
24 hours post‐IR. Interestingly Atm−/−Smg1gt/+ cells had a lower num‐
ber of foci at 24 hours post‐IR than at baseline suggesting that IR 
may induce other DNA repair pathways to repair the damage that 
were not activated in the basal state in these cells. This was not 
the case for Atm−/− cells where numbers were similar to baseline. 
We also examined cell death in response to irradiation, thymocytes 
were isolated from mice and exposed to 5Gy irradiation, and apop‐
tosis was determined by Annexin V/ PI staining and flow cytometry 
analysis. As expected from previous literature, Atm−/− thymocytes 
had a greater proportion of cells surviving at 24h (live) and a lower 
percentage of cells in late apoptosis than Smg1gt/+ or wild‐type mice 
(Figure 3D). Atm−/−Smg1gt/+ thymocytes showed no significant dif‐
ference in cell death compared with Atm−/− cells. This makes sense 
given that once DNA repair pathways were induced the level of 
DNA damage retained in Atm−/−Smg1gt/+ cells returned to the same 
level as Atm−/− cells (Figure 3B).
3.5 | Effect of Smg1 haploinsufficiency on systemic 
inflammation
Our previous investigations showed that Smg1gt/+ mice had ele‐
vated levels of tissue and serum cytokines prior to the onset of 
disease.12 Furthermore, loss of ATM can result in increased inflam‐
mation due to unrepaired DNA damage resulting in an accumula‐
tion of cytosolic DNA and subsequent pro‐inflammatory cytokine 
production.5,17 As an inflammatory microenvironment may also 
contribute to the development of haematopoietic tumours, we 
determined cytokine levels in Atm−/−Smg1gt/+ mice. Animals were 
killed between 3 and 5 months of age, and tissues and serum were 
collected. Cytokine levels were measured by real‐time PCR and 
CBA assay. In serum samples, cytokine levels were highly variable 
between individuals. For a subset of NF‐κB–dependent cytokines 
(interleukin‐6 [IL‐6], tumour necrosis factor α [TNFα], IL‐1β and 
IL‐12p70), levels were generally undetectable in wild‐type mice 
and we could observe a small difference in cytokine levels be‐
tween wild‐type and Smg1gt/+ mice, though a smaller magnitude 
difference than we had observed previously (Figure 4A). This is 
likely due to the earlier sacrifice time of the animals in this study 
compared with 6‐9 months in our original study.12 The number of 
animals with higher levels of cytokines increased in Atm−/− mice 
and Atm−/−Smg1gt/+ mice although the difference in level was not 
significantly different due to the variability between individuals 
(Figure 4A). However, it appears that mice lacking Atm and espe‐
cially when combined with Smg1 heterozygosity are more likely to 
express higher levels of these cytokines. Also of interest was the 
pattern of expression of IL‐13. IL‐13 was undetectable in wild‐type 
and expressed at low levels in Smg1gt/+ mice, two Atm−/− mice ex‐
pressed high levels of IL‐13, and half of the Atm−/−Smg1gt/+ mice 
expressed detectable IL‐13 levels (Figure 4B). As serum levels 
provide an overview of systemic inflammation, we also measured 
IL‐1β, IL‐6 and colony‐stimulating factor 1 (CSF‐1) levels by quanti‐
tative PCR (Figure 4C). The only significant differences in cytokine 
expression were IL‐1β expression in the heart with Smg1gt/+, Atm−/− 
and Atm−/−Smg1gt/+ mice all having significantly elevated levels 
compared with wild‐type. IL‐6 in the heart and lung appeared to 
     |  8157HO et al.
F I G U R E  3   Smg1 heterozygosity combined with Atm loss increases basal oxidative stress and DNA damage burden. A, Smg1 
heterozygosity combined with Atm loss increases oxidative damage to tissues. Spleens were harvested from pre‐disease animals, and 
immunofluorescence was performed for the marker of oxidative damage to DNA, 8‐oxo‐dG (green) and DAPI to highlight nuclei (blue). B, C, 
Murine embryonic fibroblasts were generated and exposed to 5 Gy irradiation (IR). Cells were fixed at the indicated time‐points post‐IR and 
stained for the presence of γH2AX as a marker of unrepaired DNA damage. The number of γH2AX foci in each cell nucleus was counted, and 
quantification is shown in panel A and example 0hr images in panel B γH2AX (green) and DAPI (blue). Statistical significance was determined 
using a t test with Welch's correction for unequal variance. Bars indicate the mean and error bars the standard error of the mean. *P < .05, 
**P < .01, ***P < .001. D, Thymocytes were isolated from mice and exposed to 5Gy irradiation (IR). At baseline and 24 h post‐IR, apoptosis 
was measured using AnnexinV/PI staining and flow cytometry. Bars indicate the mean and error bars the standard error of the mean
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be increased in Atm−/− and Atm−/−Smg1gt/+ mice but this did not 
reach statistical significance. We also measured the levels of IFNβ 
in splenic tissues but this was undetectable in nearly all samples 
(Figure 4D).
4  | DISCUSSION
Both SMG1 and ATM have been shown previously to act as tumour 
suppressors.12,27‐29 Here we demonstrated that loss of one of the 
alleles of Smg1 in addition to Atm loss resulted in more rapid cancer 
development. Also all cancers arose from the haematopoietic system 
in contrast to either Smg1+/gt or Atm−/− mice where there were a large 
proportion of haematopoietic cancers but solid cancers, particularly 
lung adenocarcinomas, were also prevalent 12,16 (Table 1). Although 
the combined loss of Smg1 and Atm did not alter the composition 
of the immune system compared with loss of Atm alone (Figure 2), 
it did result in a significant increase in basal DNA damage load and 
oxidative stress (Figure 3). In response to induced DNA damage, 
SMG1 and ATM can act in concert to regulate p53 phosphorylation 
and G1/S checkpoint activation in response to DNA damage.13,14 
When Atm or Smg1 are knocked out, it results in cells continuing to 
F I G U R E  4   Smg1 heterozygosity combined with Atm loss may increase basal inflammation. A, B, Serum was isolated from mice and 
cytokine levels analysed by cytokine bead assay. Symbols show the value for each individual animal, and bars show the average. In panel 
B, error bars show the standard error of the mean. C, Spleen, heart, lung and thymus were harvested from pre‐disease animals, RNA was 
isolated, and cytokine mRNA levels were measured by quantitative PCR. Bars show the mean and error bars the standard error of the 
mean. D, IFNβ mRNA levels were measured in spleen samples from pre‐disease animals by quantitative PCR. Symbols show the results for 
individual animals, horizontal lines the average and error bars the standard error if the mean. Statistical significance was determined using a t 
test with Welch's correction for unequal variance. *P < .05
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proliferate even in the presence of unrepaired DNA damage, failing 
to be blocked in their passage through the cell cycle at the G1/S 
phase transition, often referred to as radioresistant DNA synthe‐
sis.13,30 This is due to defective p53 phosphorylation, in the absence 
of ATM at the G1/S checkpoint. SMG1 can also control p53 acti‐
vation by regulating the expression of alternatively spliced p53 iso‐
forms.15 Further loss of either Smg1 or Atm alone results in increased 
oxidative stress and the resultant damage to DNA.2,12 As such when 
we combined loss of Atm and Smg1 in Atm−/−Smg1gt/+ mice we saw 
exacerbated oxidative damage in tissues and increased basal DNA 
damage load. Given that increased damage burden did not result in 
greater cell death in Atm−/−Smg1gt/+ cells (Figure 3C), the combined 
data suggest that cells are surviving but are more likely to develop 
an oncogenic mutation, due to low level DNA damage, which could 
contribute to the development of cancers in these animals.
ATM and SMG1 have also both been implicated in the regu‐
lation of inflammation with loss increasing basal cytokine levels 
(reviewed in 31). A low‐level, continuous inflammatory response 
or ‘smouldering’ inflammation is a pro‐tumourigenic microenviron‐
ment.32 This is particularly true for haematopoietic cancers where 
the cytokines can also act directly as growth factors; for example, 
increased IL‐6 drives B cell growth and proliferation via activation 
of STAT3.33 Along with STAT3, NF‐κB is a key transcription fac‐
tor which can drive tumourigenesis and support cancer cell sur‐
vival.34 In Atm−/−Smg1gt/+ mice, we saw a trend of increasing levels 
of NF‐κB–dependent cytokine expression indicating that there 
was ongoing NF‐κB activation in these animals (Figure 4A and 4). 
This was not consistent across all animals at a given time‐point but 
this may reflect the range of times at which Atm−/−Smg1gt/+ mice 
develop cancer. All our cytokine analysis was performed in pre‐
disease animals (3‐5 months of age showing no signs of disease 
or enlargement of haematopoietic organs upon sacrifice) based 
on the survival curve (Figure 1A). Some of these animals would 
have been much closer in time to developing cancers than oth‐
ers, and as such, only a proportion of mice had detectable tumour 
promoting cytokines at this time‐point. Interestingly, we also saw 
a significant increase in IL‐13 levels in the serum in Atm−/−Smg1gt/+ 
mice compared with wild‐type littermates (Figure 4B). IL‐13 also 
has a role in creating a pro‐tumour environment via the activa‐
tion of tumour‐associated macrophages and myeloid‐derived 
suppressor cells.35 Together these data suggest that as they age 
Atm−/−Smg1gt/+ mice may more quickly develop a pro‐tumour mi‐
croenvironment compared with control animals.
What was not increased in Atm−/−Smg1gt/+ mice was type I in‐
terferon production. Long‐term unrepaired DNA damage results in 
accumulation of DNA in the cytoplasm of cells which activates the 
cGAS/STING pathway to induce interferon (IFN) production.36 This 
has previously been demonstrated in bone marrow‐derived cells 
from Atm−/− mice and in isolated cells and tissues from rats lack‐
ing ATM expression.5,6,17 However, in tissues analysed here IFNβ 
was barely detected in any Atm−/−Smg1gt/+ mice (Figure 4D). At this 
same time–point, increased oxidative DNA damage was evident in 
spleen (Figure 3A) but it is possible that this had not persisted for 
long enough to lead to IFN induction. Alternatively, loss of SMG1 
in addition to ATM loss may limit IFNβ production by an unknown 
mechanism.
Overall, our data demonstrate that combined loss of expression 
of ATM and heterozygosity of SMG1 results in more rapid cancer de‐
velopment particularly haematopoietic cancers. Pre‐disease animals 
showed increased unrepaired DNA damage and oxidative stress and 
propensity to develop “smouldering” inflammation most clearly in 
haematopoietic tissues. The combination of persistent DNA dam‐
age and a permissive tumour microenvironment represents a likely 
mechanism resulting in increased and more rapid development of 
blood cancers. In total, this work further highlights the extensive 
crosstalk and dual regulation of pathways by members of the PIKK 
family.
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